 SOLANA BEACH, Calif., Jan. 13, 2021 GLOBE NEWSWIRE -- Evoke Pharma, Inc. Nasdaq: EVOK, a specialty pharmaceutical company focused on treatments for gastrointestinal GI disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of 2.50 per share. Gross proceeds, before underwriting discounts and commissions and estimated offering costs, are expected to be 12.5 million. Evoke has granted the underwriter a 45-day option to purchase up to 750,000 additional shares of its common stock. The offering is expected to close on or about January 19, 2021, subject to satisfaction of customary closing conditions. 